Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 101 Carcinoma, Non-Small-Cell Lung 88 Carcinoma, Renal Cell 54 Neoplasm Metastasis 37 Squamous Cell Carcinoma of Head and Neck 32 Colorectal Neoplasms 32 Carcinoma, Hepatocellular 32 Lung Neoplasms 31 Hodgkin Disease 25 Neoplasms 24 Urinary Bladder Neoplasms 21 Pancreatic Neoplasms 21 Carcinoma, Transitional Cell 20 Breast Neoplasms 19 Stomach Neoplasms 17 Brain Neoplasms 17 Prostatic Neoplasms 16 Small Cell Lung Carcinoma 15 Sarcoma 15 Multiple Myeloma 14 Head and Neck Neoplasms 14 Esophageal Neoplasms 14 Glioblastoma 11 Uterine Cervical Neoplasms 10 Rectal Neoplasms 10 Neuroendocrine Tumors 10 Lymphoma 10 Recurrence 9 Ovarian Neoplasms 9 Nasopharyngeal Carcinoma 9

Interventions

Gemcitabine 9 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Bevacizumab 4 pembrolizumab 3 Irinotecan 3 Erlotinib Hydrochloride 3 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Cisplatin 2 CP protocol 2 tislelizumab 1 tegafur-gimeracil-oteracil 1 spartalizumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × Nivolumab × Clear all

NCT04131621 2020-04-15

CheCUP

University Hospital Heidelberg

Phase 2 Unknown

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡